<DOC>
	<DOCNO>NCT01138202</DOCNO>
	<brief_summary>To assess safety , efficacy impact Lopinavir/ritonavir 400/100mg bid Lopinavir/ritonavir 600/150mg bid combination rifampicin-containing anti-TB therapy .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Safety 2 Different Doses Lopinavir/Ritonavir HIV/Tuberculosis ( TB ) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy</brief_title>
	<detailed_description>Fixed dose combination d4T+3TC+NVP ( GPOvir ) widely use Thai HIV infect since June 2002 . The prevalence NNRTI resistance increase since 2005 . Tuberculosis develop follow NNRTI-based regimen failure introduction new salvage regimen boost PI ( immune recovery syndrome ) . Although , Efavirenz base HAART preferred TB/HIV rifampicin contain antituberculosis . However , Efavirenz could use case NNRTI failure , intolerance toxicity . It remain unknown optimally treat HIV /TB population rifampicin use . Moreover , Rifabutin recommend use concomitant boost PI4 , 5 , feasible Thailand develop country due cost , toxicity dose consideration . If ritonavir-boosted LPV demonstrate suitable pharmacokinetics , well tolerate , regimen might prove extremely useful could widely implement . LPV/r potent widely available boost PI National Health System Thailand . We therefore believe strong rationale impetus study LPV/r 400/100 mg bid versus LPV/r 600/150 mg bid boosted-PI combination presence RMP , able produce satisfactory PK profile associate adequate antiretroviral potency , tolerability efficacy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>1 . Confirmed HIV positive voluntary counseling test 2 . Aged &gt; 1860years age 3 . ARV na√Øve NNRTI failure ( PI naive ) 4 . CD4+ cell count &lt; 350 cells/mm3 time diagnose TB 5 . ALT &lt; 5 time ULN 6 . Serum creatinine &lt; 1.4 mg/dl 7 . Hemoglobin &gt; 8 mg/L 8 . TB diagnose plan receive stable dos rifampicincontaining antiTB therapy least 2 week period initiation ART 9 . No active OI ( CDC class C event ) , except oral candidiasis disseminate MAC 10 . Able provide write informed consent 1 . Current use steroid ( except short course steroid IRIS ) immunosuppressive agent . 2 . Current use prohibit medication related drug pharmacokinetics . 3 . Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct trial . 4 . Unlikely able remain followup protocol define period . 5 . Patients proven suspect acute hepatitis . Patients chronic viral hepatitis eligible provide ALT , AST &lt; 5 x ULN . 6 . Karnofsky performance score &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>Lopinavir/ritonavir</keyword>
	<keyword>HIV/TB</keyword>
	<keyword>rifampicin contain anti-tuberculosis therapy</keyword>
	<keyword>Pharmacokinetics safety Lopinavir/ritonavir rifampicin contain anti-tuberculosis therapy</keyword>
</DOC>